Do Traders Think First Wave BioPharma Inc (FWBI) Can Turn Around Thursday?

First Wave BioPharma Inc (FWBI) stock is lower by 2.68% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

First Wave BioPharma Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on FWBI!

See Full FWBI Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With FWBI Stock Today?

First Wave BioPharma Inc (FWBI) stock is trading at $4.36 as of 2:57 PM on Thursday, Mar 28, a gain of $0.41, or 10.41% from the previous closing price of $3.95. The stock has traded between $3.85 and $4.55 so far today. Volume today is light. So far 49,152 shares have traded compared to average volume of 134,586 shares. To screen for more stocks like First Wave BioPharma Inc click here.

More About First Wave BioPharma Inc

First Wave BioPharma Inc is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Click Here to get the full Stock Report for First Wave BioPharma Inc stock.